Immunovant, Inc. IMVT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s accounts receivable?
- Immunovant, Inc. (IMVT) reported accounts receivable of $1.13M in Q1 2026.
- How has Immunovant, Inc.'s accounts receivable changed year-over-year?
- Immunovant, Inc.'s accounts receivable decreased by 45.6% year-over-year, from $2.08M to $1.13M.
- What is the long-term trend for Immunovant, Inc.'s accounts receivable?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s accounts receivable has grown at a -24.1% compound annual growth rate (CAGR), from $20.15M to $6.68M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.